chufangao/CTO huggingface dataset:
Clinical trial NCT01300728: Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment
Official title: A Randomized Double-Blinded Placebo-Controlled Exploratory Study of Intravenous Immunoglobulin (NewGam 10%) in Amnestic Mild Cognitive Impairment
Acronym: MCI
Sponsor: Sutter Health (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 52.0 (ACTUAL)
Number of arms: 2.0
Start date: 2011-01-01
Primary completion date: 2020-03-12
Completion date: 2020-03-12
Clinical trial NCT04655599: Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
Official title: Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome
Sponsor: Arena Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Strategic business decision
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-01-29
Primary completion date: 2021-04-13
Completion date: 2021-04-13
Plan to share individual participant data: NO
Clinical trial NCT03256045: Panobinostat, Carfilzomib, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Official title: CLBH589DUS108T: Panobinostat With Carfilzomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma: Correlation With In Vitro Chemosensitivity Testing
Sponsor: University of Washington (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated due to loss of funding and former PI left the institution
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-02-08
Primary completion date: 2021-02-05
Completion date: 2021-02-05
Limitations and caveats: Study was limited by lower accrual than expected due to: competing studies, other investigators' treatment preferences, and ultimately, the departure of the initial PI from the institution. Because of PI's departure and lab closure, the study closed to accrual after the 9th patient enrolled. Because only 9 subjects were enrolled and some in-vitro assay results are unavailable, it is difficult to analyze the in-vitro assay results and determine the parameters that predict disease response.
Clinical trial NCT04001413: Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Official title: Phase II, Adjuvant Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients With Durvalumab (MEDI4736) and MEDI0457 (INO-3112)
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor withdrew funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2019-09-17
Primary completion date: 2021-03-25
Completion date: 2021-03-25
Plan to share individual participant data: NO
Clinical trial NCT03016312: A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer (mCRPC) After Failure of an Androgen Synthesis Inhibitor And Failure of, Ineligibility For, or Refusal of a Taxane Regimen
Official title: A Phase III, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide Versus Enzalutamide Alone in Patients With Metastatic Castration-Resistant Prostate Cancer After Failure of an Androgen Synthesis Inhibitor and Failure of, Ineligibility for, or Refusal of a Taxane Regimen
Acronym: IMbassador250
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 759.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-01-10
Primary completion date: 2019-06-24
Completion date: 2022-12-20
Baseline population: Total randomised participants 759.
Clinical trial NCT02485691: Cabazitaxel Versus the Switch to Alternative AR-targeted Agent (Enzalutamide or Abiraterone) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent
Official title: A Randomized, Open Label, Multicenter Study of Cabazitaxel Versus an Androgen Receptor (AR)-Targeted Agent (Abiraterone or Enzalutamide) in mCRPC Patients Previously Treated With Docetaxel and Who Rapidly Failed a Prior AR-targeted Agent (CARD)
Acronym: CARD
Sponsor: Sanofi (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 255.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-11-09
Primary completion date: 2019-03-27
Completion date: 2021-03-15
Baseline population: Analysis was performed on Intent-to-treat (ITT) population, that included any participant who had been allocated to a randomized treatment regardless of whether the treatment kit was used, analyzed according to the treatment group allocated by randomization.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Clinical trial NCT03575104: Study to Assess the Efficacy and Safety of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
Official title: Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography Study to Assess the Efficacy and Safety of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder
Sponsor: Idorsia Pharmaceuticals Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 924.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-05-29
Primary completion date: 2020-04-09
Completion date: 2020-05-14
Plan to share individual participant data: NO
Clinical trial NCT03282760: Safety Study of Human Neural Stem Cells Injections for Secondary Progressive Multiple Sclerosis Patients
Official title: A Phase I Multicenter Study of Allogenic, Intracerebroventricular Human Neural Stem Cells Transplantation for the Experimental Treatment of Secondary Progressive Multiple Sclerosis Patients
Acronym: NSC-SPMS
Sponsor: Casa Sollievo della Sofferenza IRCCS (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 24.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-09-09
Primary completion date: 2021-05-29
Completion date: 2021-05-29
Plan to share individual participant data: YES
IPD sharing description: All IPD that underlie results in a publication
Clinical trial NCT02760615: Phase 4, Vedolizumab-4002 Post-marketing, Disease-Drug-Drug Interaction Study
Official title: An Open-Label, 2-Part, Multicenter, Post-marketing Study to Evaluate the Effect of Moderately or Severely Active Ulcerative Colitis or Crohn's Disease on Cytochrome P-450 Enzyme Substrates Compared to Healthy Subjects and the Effect of Vedolizumab Treatment on Cytochrome P-450 Enzyme Substrates in Subjects With Ulcerative Colitis or Crohn's Disease
Sponsor: Takeda (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: No enrollment
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2016-11-01
Primary completion date: 2020-08-01
Completion date: 2020-08-01
Clinical trial NCT03402178: Study to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects
Official title: A Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Studies to Assess the Safety, Tolerability, and Pharmacokinetics of E2082 in Healthy Male Subjects
Sponsor: Eisai Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Safety Review
Enrollment: 118.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-21
Primary completion date: 2020-02-20
Completion date: 2020-02-20
Clinical trial NCT05259917: A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3, Three-way Crossover Trial to Evaluate the Efficacy and Safety of Two Dose Levels of KVD900, an Oral Plasma Kallikrein Inhibitor, for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema Type I or II
Sponsor: KalVista Pharmaceuticals, Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 136.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-02-22
Primary completion date: 2023-12-31
Completion date: 2023-12-31
Plan to share individual participant data: NO
IPD sharing description: Data will not be shared until all global regulatory filings are complete
Clinical trial NCT04322227: Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects
Official title: Interventional, Randomized, Double-blind, Placebo-controlled Three-way Crossover Study Investigating the Pharmacodynamic Effects of Two Doses of Foliglurax Using Electroencephalography in Patients With Parkinson's Disease and in Healthy Subjects
Sponsor: H. Lundbeck A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Study termination due to efficacy results of another study
Enrollment: 6.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-01-23
Primary completion date: 2020-05-30
Completion date: 2020-05-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT03095287: Alphanate in Immune Tolerance Induction Therapy
Official title: A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIII/VWF (Alphanate®) in Immune Tolerance Induction Therapy in Subjects With Congenital Hemophilia A
Sponsor: Grifols Therapeutics LLC (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Terminated due to limited enrollment (non-safety related decision)
Enrollment: 2.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-01-03
Primary completion date: 2020-09-18
Completion date: 2020-09-18
Baseline population: All enrolled participants.
Plan to share individual participant data: NO
Clinical trial NCT01571791: Perioperative Ketorolac-lidocaine in the Patients With Valvular Heart Diseases During Cesarean Delivery
Official title: A Randomized Study of the Effects of Perioperative i.v. Ketorolac-lidocaine on the Hemodynamic Response in the Patients With Valvular Heart Diseases During Cesarean Delivery
Sponsor: Mansoura University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: SUSPENDED 
Why stopped: No enough recruited cases
Enrollment: 90.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2012-06-30
Primary completion date: 2021-12-31
Completion date: 2022-03-31
Clinical trial NCT02464059: Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
Official title: Cathelicidin and Vitamin D: Impact on Populations At-Risk and With COPD
Sponsor: University of North Carolina, Chapel Hill (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-11-10
Primary completion date: 2020-04-15
Completion date: 2020-04-15
Limitations and caveats: Study enrollment did not achieve targeted sample size enrollment during the time frame of the funding award.
Plan to share individual participant data: NO
IPD sharing description: Individual participant data will not be made publicly available
Clinical trial NCT05019105: Phase 1 ALKS 1140 in Healthy Adults
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Escalating Doses of ALKS 1140 With a Pilot Evaluation of Food Effect in Healthy Adult Subjects
Sponsor: Alkermes, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Sponsor Decision
Enrollment: 20.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-10-13
Primary completion date: 2022-08-23
Completion date: 2022-08-23
Plan to share individual participant data: NO
Clinical trial NCT04416048: Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19
Official title: Effect of Anticoagulation Therapy on Clinical Outcomes in Moderate to Severe Coronavirus Disease 2019 (COVID-19)
Acronym: COVID-PREVENT
Sponsor: Charite University, Berlin, Germany (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to lower COVID-19 cases and therefore difficulties with the recruitment.
Enrollment: 111.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-11-30
Primary completion date: 2021-07-20
Completion date: 2021-07-20
Plan to share individual participant data: YES
IPD sharing description: after protection period
Clinical trial NCT04360421: Use of Long-acting Bupivacaine In Lower Extremity Amputation
Official title: Use of Liposomal Bupivacaine (Exparel) In Expedited Recovery Following Lower Extremity Amputation
Sponsor: Loma Linda University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: PI left institution
Enrollment: 7.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-04-21
Primary completion date: 2023-08-01
Completion date: 2023-08-01
Plan to share individual participant data: NO
Clinical trial NCT03543410: A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression
Official title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of SEP-4199 for the Treatment of Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression)
Sponsor: Sumitomo Pharma America, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 344.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-06-26
Primary completion date: 2020-04-23
Completion date: 2020-04-23
Plan to share individual participant data: YES
IPD sharing description: IPD for this study may be made available upon request via the Vivli Center for Global Clinical Research Data website.
IPD time frame: IPD will be made available upon request within 12 months of posting the study results on ct.gov.
IPD access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Clinical trial NCT03736967: Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Official title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Assess the Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Sponsor: Regeneron Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Lack of efficacy
Enrollment: 206.0 (ACTUAL)
Number of arms: 4.0
Start date: 2018-11-12
Primary completion date: 2020-03-13
Completion date: 2020-07-28
Limitations and caveats: The decision was made by the sponsor to terminate the study on 12 Feb 2020 due to lack of efficacy. Study enrollment was not complete at that time, therefore planned sample sizes were not met. Participants discontinued study drug and transitioned into the post-treatment follow-up period. As a result of the decision to terminate the study, all statistical analyses were descriptive and no hypothesis testing was performed.
Clinical trial NCT03378063: Stem Cells for Bronchopulmonary Dysplasia
Official title: Stem Cells for Bronchopulmonary Dysplasia: a Cohort Study
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: WITHDRAWN 
Why stopped: no stell cell accessed
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-11-01
Primary completion date: 2022-12-30
Completion date: 2022-12-30
Plan to share individual participant data: UNDECIDED
Clinical trial NCT05242029: Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use
Official title: A Randomized, Double-Blind Study of Psilocybin for Opioid Use Disorder in Patients on Methadone Maintenance With Ongoing Opioid Use
Sponsor: Johns Hopkins University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Lack of funding
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2023-12-31
Primary completion date: 2024-02-29
Completion date: 2024-12-31
Plan to share individual participant data: NO
Clinical trial NCT04612725: A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
Official title: A Phase 2b Multinational, Randomised, Double-blind, Parallel- Group, 24-week Placebo-controlled Study With 28-week Extension to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)
Acronym: ARROYO
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study did not meet primary endpoint
Enrollment: 159.0 (ACTUAL)
Number of arms: 5.0
Start date: 2020-10-27
Primary completion date: 2022-10-13
Completion date: 2023-03-28
Baseline population: The full analysis set (FAS) included all randomized participants who received at least 1 dose of study drug, irrespective of their protocol adherence and continued participation in the study.
Limitations and caveats: The study was terminated early by the sponsor as the primary analysis results did not support the continued development of benralizumab for the indication of CSU.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Clinical trial NCT03573323: A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis
Official title: A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Acronym: IXORA-R
Sponsor: Eli Lilly and Company (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 1027.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-11-09
Primary completion date: 2019-07-15
Completion date: 2020-01-08
Baseline population: All randomized participants.
Plan to share individual participant data: YES
IPD sharing description: Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.
IPD time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Clinical trial NCT04729725: SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL
Official title: Strategic Alliance: Phase 1b Trial Assessing Combination of TGF-β Inhibitor and PD-1 Inhibitor Cemiplimab
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: The industry supporter discontinued the study and lead drug, SAR439459, due to toxicity.
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-02-09
Primary completion date: 2022-12-02
Completion date: 2022-12-02
Clinical trial NCT03794596: A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer
Official title: A Proof of Concept, Window Trial of the IMmunological Effects of AveLumab and Aspirin in Triple-Negative Breast Cancer
Acronym: IMpALA
Sponsor: The Christie NHS Foundation Trust (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: IP breach
Enrollment: 0.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-09-30
Primary completion date: 2021-02-28
Completion date: 2021-02-28
Plan to share individual participant data: NO
Clinical trial NCT02530931: Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease
Official title: Evaluation of Inner Ear and Brain Structures With Contrast-enhanced MRI in Patients With Meniere's Disease
Acronym: PROSPER
Sponsor: University Hospital, Grenoble (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Recruitment problem-covid
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-03-16
Primary completion date: 2020-09-30
Completion date: 2020-09-30
Clinical trial NCT04415073: A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Axatilimab for the Treatment of Hospitalized Patients With Respiratory Signs and Symptoms Secondary to Novel Coronavirus Disease (COVID-19)
Sponsor: Syndax Pharmaceuticals (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Given enrollment challenges, partly attributable to the constantly changing COVID-19 treatment landscape, the trial has been closed.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-05-30
Primary completion date: 2020-07-13
Completion date: 2020-07-13
Baseline population: This study was terminated by the Sponsor. Due to study termination and only 1 participant being enrolled there are concerns regarding participant confidentiality, therefore no data are being reported.
Limitations and caveats: This study was terminated by the Sponsor given enrollment challenges, partly attributable to the constantly changing COVID-19 treatment landscape. Due to study termination and only 1 participant being enrolled there are concerns regarding participant confidentiality, therefore no data are being reported.